Agilis Biotherapeutics And The University of South Florida Enter Into Worldwide, Exclusive License Agreement For Angelman Syndrome Gene Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis) a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has entered into an exclusive worldwide license agreement with the University of South Florida (USF) for the treatment of Angelman Syndrome (AS) using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer's Research Institute at the University of South Florida, and one of the world’s foremost AS investigators. Dr. Weeber and colleagues have developed an innovative gene therapy approach for the treatment of AS and recently published evidence of therapeutic efficacy in the gold standard mouse model.

Help employers find you! Check out all the jobs and post your resume.